OakChart

Viking Therapeutics Inc

VKTXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 8:30 AM ET

29.33+0.67 (2.34%)
2026-11-11 14:32 CET
Market cap
3,654.78 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-627.20 USD m
Free cash flow, TTM
-462.63 USD m
EPS diluted, TTM
-5.41
P/E
-
Compare

Price

VKTX against its 20, 50 and 200-day averages
2050200beatmiss
25.0030.0035.0040.0020.6M41.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VKTXclose 29.3320-day 26.5050-day 29.56200-day 32.1929.33

32.0% under 43.15 on 12 Nov 2025. Last 15 sessions, 26.4% high to low

Profile

VKTX
52-week range, 29% of the way up
23.8243.15

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

IndexRUI
Employees53
IPOApr 29, 2015
Beta0.75
ATR, 14d1.80
Rel volume0.07
Short float19.52%
Insider own2.93%
Inst own60.40%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap3.74B
Enterprise Value3.04B
Income-627.20M
Sales0.00M
Book/sh4.62
Cash/sh7.53
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees53
IPOApr 29, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B6.35
P/C3.90
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.27
Current Ratio7.27
Debt/Eq0.43
LT Debt/Eq0.43
Option/ShortYes / Yes

Earnings

EPS (ttm)-5.41
EPS next Y-5.03
EPS next Q-1.38
EPS this Y-64.65%
EPS next Y4.18%
EPS next 5Y-7.24%
EPS past 3/5Y-52.71% -42.46%
Sales past 3/5Y- -
EPS Y/Y TTM-155.21%
Sales Y/Y TTM-
EPS Q/Q-91.98%
Sales Q/Q-
EarningsOct 28 AMC
EPS/Sales Surpr.-45.81% -

Ownership

Insider Own2.93%
Insider Trans-4.79%
Inst Own60.40%
Inst Trans1.81%
ROA-73.07%
ROE-96.37%
ROIC-74.38%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2010.68%
SMA50-0.77%
SMA200-8.90%
Trades-

Technical

Shs Outstand127.52M
Shs Float123.79M
Short Float19.52%
Short Ratio4.84
Short Interest24.16M
52W High43.15 -32.03%
52W Low23.82 23.13%
Volatility7.79% 6.45%
ATR (14)1.80
RSI (14)55.47
Beta0.75
Rel Volume0.07
Avg Volume4.99M
Volume17,670

Performance

Perf Week4.86%
Perf Month10.06%
Perf Quarter-10.96%
Perf Half Y-7.48%
Perf YTD-16.63%
Perf Year-27.76%
Perf 3Y199.90%
Perf 5Y370.03%
Perf 10Y2566.12%
Recom1.19
Target Price95.32
Prev Close28.66
Price29.33
Change %2.34%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 15, 2026InitiatedUUBSBuy$94+220.5%
May 28, 2026InitiatedLLake StreetBuy$89+203.4%
May 27, 2026ResumedTTruistBuy$83+183.0%
Mar 26, 2026InitiatedWWolfe ResearchPeer Perform
Oct 29, 2025InitiatedCCanaccord GenuityBuy$106+261.4%
Apr 29, 2025InitiatedCCantor FitzgeraldOverweight$104+254.6%
Apr 08, 2025InitiatedGGoldmanNeutral$30+2.3%
Feb 13, 2025InitiatedBScotiabankSector Outperform$102+247.8%
Feb 07, 2025InitiatedCCitigroupNeutral$38+29.6%
Dec 02, 2024InitiatedPPiper SandlerOverweight

Peers

Mkt cap
TickerCompanyMkt cap
GPCRStructure Therapeutics Inc ADR1.64B
ALTAltimmune Inc389.03M
MDGLMadrigal Pharmaceuticals Inc10.05B
SEPNSepterna Inc2.49B
LLYLilly(Eli) & Co1331.10B
NVONovo Nordisk ADR136.14B
RYTMRhythm Pharmaceuticals Inc7.89B
AMGNAMGEN Inc249.85B
WVEWave Life Sciences Inc682.41M
ARWRArrowhead Pharmaceuticals Inc6.99B

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lian BrianPresident & CEOJul 29 '26Sale33.32148,5174,947,8882,572,441Jul 29 08:07 PM
ZANTE GREGChief Financial OfficerJul 29 '26Sale33.4721,217710,141212,204Jul 29 08:06 PM
Mancini MariannaChief Operating OfficerJul 29 '26Sale33.4718,217609,636422,760Jul 29 08:06 PM
BRIAN LIANOfficerJul 29 '26Proposed Sale33.32148,5174,947,888Jul 29 04:18 PM
GREG ZANTEOfficerJul 29 '26Proposed Sale33.4721,217710,141Jul 29 04:04 PM
MARIANNA MANCINIOfficerJul 29 '26Proposed Sale33.4718,217609,636Jul 29 04:03 PM
Aubuchon Neil WilliamChief Commercial OfficerMar 10 '26Buy33.504,475149,9124,475Mar 10 06:20 PM
ZANTE GREGChief Financial OfficerJan 05 '26Sale32.9057,6611,896,969189,891Jan 05 08:31 PM
Mancini MariannaChief Operating OfficerJan 05 '26Sale32.9857,6611,901,405409,190Jan 05 08:31 PM
Lian BrianPresident & CEOJan 05 '26Sale32.96233,4097,692,1212,499,291Jan 05 08:28 PM
FOEHR MATTHEW WDirectorJan 02 '26Option Exercise3.3316,00053,280148,036Jan 05 08:25 PM
FOEHR MATTHEW WDirectorJan 02 '26Sale35.1116,000561,694132,036Jan 05 08:25 PM
MARIANNA MANCINIOfficerJan 05 '26Proposed Sale32.9857,6611,901,406Jan 05 04:32 PM
GREG ZANTEOfficerJan 05 '26Proposed Sale32.9857,6611,901,470Jan 05 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
XBIState Street SPDR S&P Biotech ETFAUM: 10.53B
VBVanguard Morningstar Small-Cap ETFAUM: 79.96B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.56B
VXFVanguard Extended Market Index ETFAUM: 30.61B
SCHASchwab U.S. Small-Cap ETFAUM: 22.32B
IWRiShares Russell Mid-Cap ETFAUM: 58.75B
VHTVanguard Health Care ETFAUM: 21.40B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 213.08M
IWDiShares Russell 1000 Value Index FundAUM: 84.65B

News

latest 14 of 206
  • The FDA Ordered GLP-1 Vision-Loss Warnings For Some Products. Shares of Eli Lilly and Novo Nordisk Were Unfazed. (International Business Times)
  • Viking Therapeutics Announces Two Poster Presentations at ObesityWeek 2026 (PR Newswire) +8.01%
  • Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire) +7.21%
  • VKTX Stock Slides Overnight After Q3 Loss: CEOs Obesity Drug Launch Timeline Frustrates Retail (Stocktwits) +5.91%
  • Viking Therapeutics Misses As Spending Jumps, But Maintenance Data And A $960 Million Cash Pile Strengthen The VK2735 Story (Earnings Whispers)
  • Loading…
  • Viking Therapeutics falls on third quarter loss miss (Investing.com)
  • Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
  • After Wegovy and Zepbound, 6 weight-loss drugs in development (Quartz)
  • Viking Therapeutics Heads Into Q3 With Shares Near Lows And Spending Under The Microscope (Earnings Whispers)
  • Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026 (PR Newswire)
  • Vikings Key Obesity Pill Enters Phase 3 Trial Heres What Investors Need To Know (Stocktwits)
  • Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity (PR Newswire)
  • Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months (TIKR)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-28-1.550-1.063-1.5500.000.0020
2026Q22026-07-29-1.100-1.233-1.1010.000.0018
2026Q12026-04-29-1.370-0.976-1.3700.000.0017
2025Q42026-02-11-1.380-0.890-1.3830.000.0016
2025Q32025-10-22-0.810-0.710-0.8080.000.0016
2025Q22025-07-23-0.580-0.447-0.5850.000.0019
2025Q12025-04-23-0.410-0.328-0.4070.000.0016
2024Q42025-02-05-0.320-0.276-0.3180.000.0015
2024Q32024-10-23-0.220-0.243-0.2250.000.0012
2024Q22024-07-24-0.200-0.263-0.2020.000.0013
2024Q12024-04-24-0.260-0.277-0.2640.000.0010
2023Q42024-02-07-0.250-0.254-0.2460.000.0010
2023Q32023-10-25-0.230-0.219-0.2260.000.0011
2023Q22023-07-26-0.190-0.193-0.1940.000.0011
2023Q12023-04-26-0.250-0.240-0.2490.000.0010
2022Q42023-02-08-0.260-0.232-0.2550.000.0010

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.360-0.407-0.3580.000.00
2020FY-0.540-0.549-0.5440.000.00
2021FY-0.710-0.738-0.7120.000.00
2022FY-0.900-0.877-0.8960.000.00
2023FY-0.910-0.924-0.9100.000.00
2024FY-1.010-0.963-1.0090.000.00
2025FY-3.190-2.722-3.1900.000.00
2026FY--5.252--0.00
2027FY--5.033--0.00
2028FY--3.934--217.16
2029FY--1.691--482.54
2030FY-1.665--1,149

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-2914000.000.000.00
2026Q4S2026-10-2814000.000.000.00
2026Q4S2026-08-0714000.000.000.00
2026Q4S2026-07-3013000.000.000.00
2026Q4S2026-05-2713000.000.000.00
2026Q4S2026-05-2312000.000.000.00
2026Q4S2026-04-3013000.000.000.00
2026Q4S2026-02-1211000.000.000.00
2026Q4S2025-12-187000.000.000.00
2026Q4S2025-11-116000.000.000.00
2026Q4S2025-11-106000.000.000.00
2026Q4S2025-11-096000.000.000.00
2026Q4S2025-11-086000.000.000.00
2026Q4S2025-11-076000.000.000.00

Estimate history

EPS, annual-0.79-0.383-0.358-0.544-0.712-0.896-0.91-1.009-3.192-5.4058
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.225-0.318-0.407-0.585-0.808-1.383-1.37-1.101-1.552
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual35.81771.74272.41473.21678.24878.257100.114111.574114.793127.521
Period201720182019202020212022202320242025MRQ
Shares, quarterly111.435111.574112.289112.33112.447114.793115.894116.653127.521
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.490.430.350.290.290.300.280.260.00
Gross Profit-0.49-0.43-0.35-0.29-0.29-0.30-0.28-0.260.00
Selling, General and Administrative Excl. Other648.08392.91150.57100.5370.0655.3942.3832.4326.16
Research and Development586.17344.95101.6463.8154.2344.9831.9323.5619.04
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-648.57-393.34-150.92-100.83-70.36-55.68-42.66-32.69-26.16
Interest Expense0.090.060.090.090.060.020.110.150.56
Unusual Expense0.000.000.000.00-0.000.000.00-1.40
Net Income Before Taxes-627.20-359.64-109.96-85.89-68.87-54.99-39.49-25.78-22.06
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-627.20-359.64-109.96-85.89-68.87-54.99-39.49-25.78-22.06
Net Income From Continuing Operations-627.20-359.64-109.96-85.89-68.87-54.99-39.49-25.78-22.06
Net Income-627.20-359.64-109.96-85.89-68.87-54.99-39.49-25.78-22.06
EPS (Recurring)-5.31-3.19-1.01-0.91-0.90-0.71-0.54-0.36-0.40
EPS (Basic, Before Extraordinaries)-5.41-3.19-1.01-0.91-0.90-0.71-0.54-0.36-0.38
EPS (Diluted)-5.41-3.19-1.01-0.91-0.90-0.71-0.54-0.36-0.38
EBITDA-648.08-392.91-150.57-100.53-70.06-55.39-42.38-32.43-26.16
Non-Operating Income (Expense)21.4633.7641.0515.021.550.713.277.053.26
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense47.9540.8229.7116.756.856.105.822.732.61
Shares Outstanding127.52114.79111.57100.1178.2678.2573.2272.4171.74
Market Capitalization3,654.783,654.784,484.181,861.54720.87359.88410.72579.56546.67

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.160.160.090.090.110.110.110.11
Gross Profit-0.16-0.16-0.09-0.09-0.11-0.11-0.11-0.11
Selling, General and Administrative Excl. Other186.95132.44164.04164.6498.4574.4655.3646.13
Research and Development166.80115.75150.15153.4689.9560.1541.3930.99
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-187.11-132.60-164.12-164.74-98.56-74.57-55.47-46.24
Interest Expense0.090.000.000.000.010.020.020.02
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-183.19-128.02-158.32-157.66-90.79-65.56-45.63-35.42
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-183.19-128.02-158.32-157.66-90.79-65.56-45.63-35.42
Net Income From Continuing Operations-183.19-128.02-158.32-157.66-90.79-65.56-45.63-35.42
Net Income-183.19-128.02-158.32-157.66-90.79-65.56-45.63-35.42
EPS (Recurring)-1.55-1.10-1.37-1.38-0.81-0.58-0.41-0.32
EPS (Basic, Before Extraordinaries)-1.55-1.10-1.37-1.38-0.81-0.58-0.41-0.32
EPS (Diluted)-1.55-1.10-1.37-1.38-0.81-0.58-0.41-0.32
EBITDA-186.95-132.44-164.04-164.64-98.45-74.46-55.36-46.13
Non-Operating Income (Expense)4.014.585.807.087.789.049.8610.85
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense17.8911.1310.348.597.3413.5511.355.67
Shares Outstanding127.52116.65115.89114.79112.45112.33112.29111.57
Market Capitalization3,654.784,529.303,760.133,976.612,955.052,976.222,710.794,484.18

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments705.74902.61362.08155.49202.10248.39275.64301.5220.58
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets9.864.605.1511.558.437.727.860.611.28
Total Current Assets715.60907.22367.23167.04210.53256.10283.50302.1321.85
Net Property, Plant & Equipment0.091.001.131.420.030.320.600.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.050.100.140.070.110.080.160.180.27
Total Assets715.73908.32368.49168.53210.66256.50284.26302.3122.12
Short Term Debt Incl. Current Port. of LT Debt0.140.490.320.300.030.330.300.003.45
Accounts Payable53.259.817.518.531.443.992.430.961.53
Other Current Liabilities23.2817.1111.3013.117.307.814.043.593.68
Total Current Liabilities76.6727.4119.1421.958.7812.136.784.558.66
Long Term Debt0.000.630.941.260.000.030.360.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.010.00
Total Liabilities76.6728.0420.0723.218.7812.167.144.568.66
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity639.06880.28348.42145.32201.88244.34277.12297.7513.46
Total Shareholders Equity639.06880.28348.42145.32201.88244.34277.12297.7513.46
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity639.06880.28348.42145.32201.88244.34277.12297.7513.46
Total Liabilities & Stockholders Equity715.73908.32368.49168.53210.66256.50284.26302.3122.12
Book Value Per Share5.577.893.481.862.583.343.834.150.38
Tangible Book Value Per Share5.577.893.481.862.583.343.834.150.38
Full-Time Employees533627211720191511
Price to Book Ratio6.214.925.064.761.781.692.101.8451.98
Return on Assets-44.29-17.22-31.99-36.32-23.54-14.61-8.79-13.60-112.27
Return on Equity-47.34-17.90-34.79-39.67-24.65-15.15-8.97-14.18-191.35
Return on Invested Capital-56.28-12.48-24.59-46.98-27.24-16.16-9.29-7.41-152.83
Quick Ratio9.3333.0919.197.6123.9821.1241.8366.402.52
Current Ratio9.3333.0919.197.6123.9821.1241.8366.402.52

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-627.20-359.64-109.96-85.89-68.87-54.99-39.49-25.78-22.06
Depreciation0.490.430.350.290.290.300.280.26-
Other Funds (Non Cash)43.3631.5512.468.689.9910.049.724.552.48
Funds from Operations-583.34-327.66-97.15-76.92-58.59-44.66-29.49-20.97-19.58
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital120.7148.989.363.5510.19-2.937.72-3.780.82
Cash from Operating Activities-462.63-278.69-87.79-73.38-48.40-47.59-21.78-24.75-18.75
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments331.75341.39-553.37-179.0954.7537.9641.577.46-265.73
Purchase of Investments-195.26-418.04-1,113.37-478.30-121.43-168.01-280.64-362.41-348.20
Sale Or Maturity of Investments527.02759.42560.00299.22176.18205.97322.20369.8782.47
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities331.75341.39-553.37-179.0954.7537.9641.577.46-265.73
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock300.652.49607.91276.53-5.977.591.251.04304.24
Repurchase of Common Pref Stock0.000.000.000.00-6.790.000.000.000.00
Sale of Common Pref Stock300.652.49607.91276.530.837.591.251.04304.24
Proceedsfrom Stock Options297.270.00597.09269.76-0.02-0.05-0.03-0.07295.84
Issuance or Reduction of Debt, Net251.000.000.000.000.000.000.000.00-3.83
Change in Long Term Debt251.000.000.000.000.000.000.000.00-3.83
Issuance of Long Term Debt251.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-3.83
Net Financing Active Other Cash Flow156.6773.954.56-5.1510.13-0.71-0.30-0.15-0.13
Other Financing Activities Uses0.000.00-42.10-7.12-1.53-0.71-0.30-0.15-0.13
Cash from Financing Activities708.3276.44612.46271.384.166.880.950.89300.27
Exchange Rate Effect-0.00-0.01-0.15-0.03-0.26----
Net Change in Cash577.43139.13-28.8418.8810.26-2.7520.74-16.4015.79
Free Cash Flow-462.63-278.69-87.79-73.38-48.40-47.59-21.78-24.75-18.75
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments959.81501.66602.96705.74714.57807.72
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets13.1915.905.259.8624.1319.29
Total Current Assets973.00517.56608.21715.60738.70827.02
Net Property, Plant & Equipment3.854.010.000.090.670.78
Total Investments and Advances0.200.210.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.110.110.030.050.050.05
Total Assets977.17521.90608.24715.73739.41827.85
Short Term Debt Incl. Current Port. of LT Debt0.020.160.000.140.440.47
Accounts Payable82.1369.0167.1853.254.415.49
Other Current Liabilities51.7440.4839.1423.2821.2226.02
Total Current Liabilities133.90109.66106.3376.6726.0731.98
Long Term Debt254.673.920.000.000.320.41
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities388.57113.58106.3376.6726.3932.39
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity588.60408.32501.92639.06713.03795.46
Total Shareholders Equity588.60408.32501.92639.06713.03795.46
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity588.60408.32501.92639.06713.03795.46
Total Liabilities & Stockholders Equity977.17521.90608.24715.73739.41827.85
Book Value Per Share4.623.504.335.576.347.08
Tangible Book Value Per Share4.623.504.335.576.347.08
Full-Time Employees746559535149
Price to Book Ratio6.219.015.855.553.713.51
Return on Assets-73.07-79.24-64.04-44.29-28.31-19.33
Return on Equity-96.37-88.85-70.04-47.34-29.23-19.99
Return on Invested Capital-21.72-31.06-31.54-24.67-12.73-8.24
Quick Ratio7.274.725.729.3328.3425.86
Current Ratio7.274.725.729.3328.3425.86

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-183.19-128.02-158.32-157.66-90.79-65.56
Depreciation0.160.160.090.090.110.11
Other Funds (Non Cash)17.1910.339.046.805.3111.18
Funds from Operations-165.84-117.54-149.19-150.77-85.36-54.27
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital27.65-7.6435.2265.48-8.647.20
Cash from Operating Activities-138.19-125.17-113.98-85.29-94.00-47.06
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments92.52109.4354.1975.61160.0342.51
Purchase of Investments-12.28-70.05-72.44-40.49-21.45-123.48
Sale Or Maturity of Investments104.80179.49126.63116.11181.48165.98
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities92.52109.4354.1975.61160.0342.51
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock298.031.010.451.160.480.51
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock298.031.010.451.160.480.51
Proceedsfrom Stock Options297.270.000.000.000.000.00
Issuance or Reduction of Debt, Net251.000.000.000.000.000.00
Change in Long Term Debt251.000.000.000.000.000.00
Issuance of Long Term Debt251.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow48.5222.5711.6373.950.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities597.5523.5912.0875.100.480.51
Exchange Rate Effect-0.030.000.020.01-0.01-0.01
Net Change in Cash551.857.84-47.6965.4366.50-4.06
Free Cash Flow-138.19-125.17-113.98-85.29-94.00-47.06

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.52%24.2M123.8M4.75M
2026-10-1520.69%25.5M123.4M4.34M
2026-09-3021.06%25.9M123.1M3.77M
2026-09-1520.00%22.6M112.9M2.24M
2026-08-3119.65%22.2M112.9M2.27M
2026-08-1419.73%22.3M112.9M2.29M
2026-07-3119.91%22.5M113.2M2.34M
2026-07-1520.52%23.2M112.9M2.42M
2026-06-3020.83%23.5M112.9M2.38M
2026-06-1520.67%23.3M112.8M2.20M
2026-05-2919.82%22.4M112.9M2.27M
2026-05-1519.74%22.3M112.9M2.36M
2026-04-3020.07%22.7M112.9M2.66M
2026-04-1520.52%23.1M112.6M2.68M
2026-03-3121.41%24.0M112.1M3.03M
2026-03-1321.67%24.3M112.1M2.95M
2026-02-2721.69%24.3M112.1M2.98M
2026-02-1323.33%26.2M112.1M3.08M
2026-01-3023.76%26.1M109.7M3.22M
2026-01-1522.91%25.1M109.7M3.55M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call16.0010.8014.8012.878.9108.004.000.992-0.0290.001
call17.009.8013.8011.878.24511.0013.000.992-0.0290.001
call18.009.3512.8010.947.62016.0028.000.991-0.0280.001
call19.007.8011.8010.017.02820.0026.000.990-0.0280.001
call20.007.1010.709.476.31319.009.000.988-0.0280.001
call21.006.359.357.625.2686.009.000.987-0.0270.001
call21.505.359.307.995.6643.002.000.986-0.0270.001
call22.006.258.806.705.4062588.000.985-0.0260.001
call22.504.858.307.045.1534.003.000.984-0.0260.001
call23.005.257.806.164.90222726.000.976-0.0350.001
call23.503.257.305.534.65545.0046.000.975-0.0340.001
call24.002.796.805.094.41152.0016.000.972-0.0330.002
call24.502.306.304.814.16919.006.000.908-0.1060.004
call25.003.354.753.602.7872001.000.900-0.1020.004
call25.502.984.353.202.70021.0021.000.889-0.0980.005
call26.002.593.953.002.48754558.000.851-0.1180.006
call26.502.093.601.852.44092.0024.000.803-0.1390.007
call27.001.372.751.901.9249092710.722-0.1940.008
call27.501.192.651.922.04241050.000.667-0.2060.009
call28.000.862.151.801.80691563.000.606-0.2150.010
call28.500.502.291.622.05826012.000.544-0.2620.010
call29.000.461.000.531.27339497.000.486-0.2460.010
call29.500.310.890.601.2368172400.423-0.2270.010
call30.000.130.650.701.1651,2712620.382-0.2420.010
call30.500.120.500.211.15571033.000.314-0.2060.009
call31.000.060.200.130.89733193.000.202-0.1270.007
call31.500.070.170.290.96161.002.000.145-0.0990.006
call32.000.010.100.050.9224272160.095-0.0700.004
call32.500.010.140.071.01610429.000.088-0.0720.004
call33.000.000.060.060.91389.003.000.044-0.0380.002
call33.500.000.360.060.99068.000.000.041-0.0390.002
call34.000.000.050.011.0652562670.038-0.0400.002
call34.500.002.130.111.1388.000.000.036-0.0400.002
call35.000.000.260.031.15393.0011.000.028-0.0330.002
call35.500.000.660.011.2207.004.000.027-0.0330.002
call36.000.000.360.011.28422.000.000.025-0.0340.001
call36.500.002.130.001.3501.000.000.024-0.0340.001
call37.000.002.130.071.41315.000.000.023-0.0350.001
call38.000.002.130.141.5344.000.000.022-0.0360.001
call39.000.001.700.601.6512.000.000.021-0.0360.001
call40.000.000.901.551.76359.001.000.019-0.0370.001
call41.000.002.130.241.8724.000.000.018-0.0380.001
call42.000.002.130.011.9763.000.000.018-0.0380.001
call43.000.002.130.172.0783.000.000.017-0.0390.001
call45.000.002.131.852.27119.001.000.016-0.0400.001
put16.000.002.130.002.8830.000.00-0.008-0.0270.001
put17.000.002.130.002.6100.000.00-0.008-0.0270.001
put18.000.002.130.002.3510.000.00-0.009-0.0260.001
put19.000.002.130.112.1042.000.00-0.010-0.0260.001
put20.000.002.130.041.8696.000.00-0.012-0.0250.001
put21.000.002.130.021.6434.000.00-0.013-0.0250.001
put21.500.002.130.081.5344.000.00-0.014-0.0240.001
put22.000.002.130.051.42633.000.00-0.015-0.0240.001
put22.500.000.020.041.41514.0020.00-0.014-0.0230.001
put23.000.001.200.101.2961350.00-0.024-0.0320.001
put23.500.002.130.041.1889.000.00-0.025-0.0310.001
put24.000.000.030.021.08149.0012.00-0.028-0.0310.002
put24.500.002.140.081.40710.0020.00-0.092-0.1030.004
put25.000.002.160.051.2711202.00-0.100-0.0990.004
put25.500.010.160.061.13434.003.00-0.111-0.0950.005
put26.000.020.190.071.05317210.00-0.146-0.1120.006
put26.500.100.230.070.97435.0013.00-0.204-0.1450.007
put27.000.070.480.151.112274147-0.278-0.1910.008
put27.500.010.450.300.93192.000.00-0.333-0.2030.009
put28.000.050.600.420.8991105.00-0.394-0.2120.010
put28.500.070.880.740.95887.004.00-0.456-0.2590.010
put29.000.501.700.921.51073.0049.00-0.517-0.2300.010
put29.500.351.880.751.39712.0010.00-0.577-0.2240.010
put30.000.672.911.702.11910894.00-0.618-0.2390.010
put30.500.773.050.001.9301.000.00-0.686-0.2020.009
put31.000.393.555.412.0946.000.00-0.798-0.1240.007
put31.500.934.400.002.6160.000.00-0.855-0.0960.006
put32.001.295.300.003.1820.000.00-0.905-0.0660.004
put32.501.765.750.003.2790.000.00-0.912-0.0690.004
put33.002.255.806.972.9455.000.00-0.956-0.0340.002
put33.502.746.450.003.2410.000.00-0.959-0.0350.002
put34.003.307.006.303.4255.000.00-0.962-0.0360.002
put34.503.757.400.003.4420.000.00-0.964-0.0370.002
put35.004.257.958.553.6191.000.00-0.972-0.0290.002
put35.504.708.200.003.4530.000.00-0.973-0.0300.002
put36.005.208.959.493.8510.000.00-0.975-0.0300.001
put36.505.759.700.004.2420.000.00-0.976-0.0300.001
put37.006.2510.209.004.3520.000.00-0.977-0.0310.001
put38.007.2010.508.863.7361.001.00-0.978-0.0320.001
put39.008.2511.659.794.1151.001.00-0.979-0.0320.001
put40.009.2012.5510.874.1691.001.00-0.981-0.0330.001
put41.0010.2514.2511.805.2012.001.00-0.982-0.0330.001
put42.0011.2015.0014.155.0810.000.00-0.982-0.0340.001
put43.0012.2515.6515.084.8060.000.00-0.983-0.0340.001
put45.0014.2017.6518.905.1130.000.00-0.984-0.0350.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-09-288-KCurrent report2026-09-23SEC
2026-09-25424B5SEC
2026-09-25424B5SEC
2026-09-24FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-09-24305B2Application for designation of a new trustee under the Trust Indenture ActSEC
2026-09-23424B5SEC
2026-09-23424B5SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-01SEC
2026-08-073Initial statement of beneficial ownership of securities2026-08-01SEC
2026-07-30S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-07-29144Filing for proposed sale of securities under Rule 144.SEC
2026-07-29144Filing for proposed sale of securities under Rule 144.SEC
2026-07-29144Filing for proposed sale of securities under Rule 144.SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-033Initial statement of beneficial ownership of securities2026-06-01SEC
2026-05-268-KCurrent report2026-05-19SEC
2026-04-30SCHEDULE 13GSEC
2026-04-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-298-KCurrent report2026-04-29SEC
2026-04-01ARSAnnual report to security holders. 2025-12-31SEC
2026-04-01DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07006.27M3
2026-060000
2026-050000
2026-040000
2026-03149.91K100
2026-020000
2026-010012.05M4
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC7.74%
BlackRock, Inc.5.33%
STATE STREET CORP4.83%
VANGUARD CAPITAL MANAGEMENT LLC4.35%
VANGUARD PORTFOLIO MANAGEMENT LLC3.86%
TWO SIGMA INVESTMENTS, LP3.39%
MORGAN STANLEY3.00%
AMERIPRISE FINANCIAL INC1.86%
GEODE CAPITAL MANAGEMENT, LLC1.73%
AMERICAN CENTURY COMPANIES INC1.56%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.09%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.01%
VANGUARD SMALL-CAP INDEX FUND2.18%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.26%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
Heritage Fund1.14%
Fidelity Advisor Growth Opportunities Fund0.91%
Fidelity Extended Market Index Fund0.49%
Schwab U.S. Small-Cap ETF0.47%
Select Health Care Portfolio0.46%

OakChart. VKTX. Cached 15 minutes.